BCL2 and acute myeloid leukemia: This may have resulted from the reduced sensitivity of AML cells to venetoclax observed in CM relative to MCM, mediated by a switch from BCL-2- to BCL-XL-dependent cell survival that has a less pronounced effect on navitoclax32.